Expression of 15-hydroxyprostaglandin Dehydrogenase and Cyclooxygenase-2 in Non-small Cell Lung Cancer: Correlations with Angiogenesis and Prognosis

Overview

Journal Oncol Lett

Specialty Oncology

Date 2014 Sep 10

PMID 25202373

Citations 7

Authors

Ying Li

Suli Li

Dan Sun

Linlin Song

Xinmin Liu

Affiliations

Soon will be listed here.

Abstract

The aim of the present study was to investigate the function of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) and cyclooxygenase-2 (COX-2) in angiogenesis and their association with the prognosis of non-small cell lung cancer (NSCLC). Using immunohistochemical staining, the expression of 15-PGDH and COX-2, and the microvessel density (MVD) levels were evaluated in 35 NSCLC specimens. Paracancerous normal lung tissue was collected as control samples from six patients. The correlation of 15-PGDH with COX-2, clinicopathological characteristics, MVD and overall survival (OS) was studied. NSCLC tissues showed a significantly lower expression level of 15-PGDH (P=0.009) and a significantly higher expression level of COX-2 (P=0.004) compared with normal lung tissue. The expression level of 15-PGDH was negatively correlated with MVD (P<0.001) and COX-2 expression (P=0.032). A low expression level of 15-PGDH, a high expression level of COX-2 and high levels of MVD were significantly correlated with a shorter OS time (15-PGDH, P<0.0001; COX-2, P=0.038; MVD, P<0.0001). This study provided clinical evidence that a low expression level of 15-PGDH is associated with a poor prognosis in NSCLC. Furthermore, it was shown that 15-PGDH and COX-2 reciprocally regulate cancer angiogenesis, which may affect the prognosis of patients with NSCLC.

Citing Articles

Overexpression of 15-Hydroxyprostaglandin Dehydrogenase Inhibits A549 Lung Adenocarcinoma Cell Growth via Inducing Cell Cycle Arrest and Inhibiting Epithelial-Mesenchymal Transition.

Wang W, Yang C, Deng H Cancer Manag Res. 2021; 13:8887-8900.

PMID: 34876851 PMC: 8643138. DOI: 10.2147/CMAR.S331222.

Intersecting Mechanisms of Hypoxia and Prostaglandin E2-Mediated Inflammation in the Comparative Biology of Oral Squamous Cell Carcinoma.

Nasry W, Martin C Front Oncol. 2021; 11:539361.

PMID: 34094895 PMC: 8175905. DOI: 10.3389/fonc.2021.539361.

Clinical benefit of COX-2 inhibitors in the adjuvant chemotherapy of advanced non-small cell lung cancer: A systematic review and meta-analysis.

Xu Y, Long X, Han M, Huang M, Lu J, Sun X World J Clin Cases. 2021; 9(3):581-601.

PMID: 33553396 PMC: 7829738. DOI: 10.12998/wjcc.v9.i3.581.

The first case of primary hypertrophic osteoarthropathy with soft tissue giant tumors caused by HPGD loss-of-function mutation.

Pang Q, Xu Y, Qi X, Jiang Y, Wang O, Li M Endocr Connect. 2019; 8(6):736-744.

PMID: 31063976 PMC: 6547301. DOI: 10.1530/EC-19-0149.

Cyclooxygenase-2 expression is associated with initiation of hepatocellular carcinoma, while prostaglandin receptor-1 expression predicts survival.

Yang H, Jiang J, Yang Y, Yang X, Guo Z, Qi Y World J Gastroenterol. 2016; 22(39):8798-8805.

PMID: 27818595 PMC: 5075554. DOI: 10.3748/wjg.v22.i39.8798.

References

Lim S, Cho H, Lee T, Choi C, Min Y, Kim S . Impacts of cytosolic phospholipase A2, 15-prostaglandin dehydrogenase, and cyclooxygenase-2 expressions on tumor progression in colorectal cancer. Yonsei Med J. 2010; 51(5):692-9. PMC: 2908865. DOI: 10.3349/ymj.2010.51.5.692. View

Lim K, Han C, Xu L, Isse K, Demetris A, Wu T . Cyclooxygenase-2-derived prostaglandin E2 activates beta-catenin in human cholangiocarcinoma cells: evidence for inhibition of these signaling pathways by omega 3 polyunsaturated fatty acids. Cancer Res. 2008; 68(2):553-60. DOI: 10.1158/0008-5472.CAN-07-2295. View

Huang G, Eisenberg R, Yan M, Monti S, Lawrence E, Fu P . 15-Hydroxyprostaglandin dehydrogenase is a target of hepatocyte nuclear factor 3beta and a tumor suppressor in lung cancer. Cancer Res. 2008; 68(13):5040-8. PMC: 2762106. DOI: 10.1158/0008-5472.CAN-07-6575. View

Backlund M, Mann J, Holla V, Buchanan F, Tai H, Musiek E . 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J Biol Chem. 2004; 280(5):3217-23. PMC: 1847633. DOI: 10.1074/jbc.M411221200. View

Lim K, Han C, Dai Y, Shen M, Wu T . Omega-3 polyunsaturated fatty acids inhibit hepatocellular carcinoma cell growth through blocking beta-catenin and cyclooxygenase-2. Mol Cancer Ther. 2009; 8(11):3046-55. PMC: 2783299. DOI: 10.1158/1535-7163.MCT-09-0551. View

Ding Y, Tong M, Liu S, Moscow J, Tai H . NAD+-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor in lung cancer. Carcinogenesis. 2004; 26(1):65-72. DOI: 10.1093/carcin/bgh277. View

Krishnan A, Swami S, Feldman D . Vitamin D and breast cancer: inhibition of estrogen synthesis and signaling. J Steroid Biochem Mol Biol. 2010; 121(1-2):343-8. DOI: 10.1016/j.jsbmb.2010.02.009. View

Brecht K, Weigert A, Hu J, Popp R, Fisslthaler B, Korff T . Macrophages programmed by apoptotic cells promote angiogenesis via prostaglandin E2. FASEB J. 2011; 25(7):2408-17. DOI: 10.1096/fj.10-179473. View

Meert A, Paesmans M, Martin B, Delmotte P, Berghmans T, Verdebout J . The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer. 2002; 87(7):694-701. PMC: 2364252. DOI: 10.1038/sj.bjc.6600551. View

10.

Quidville V, Segond N, Lausson S, Frenkian M, Cohen R, Jullienne A . 15-Hydroxyprostaglandin-dehydrogenase is involved in anti-proliferative effect of non-steroidal anti-inflammatory drugs COX-1 inhibitors on a human medullary thyroid carcinoma cell line. Prostaglandins Other Lipid Mediat. 2006; 81(1-2):14-30. DOI: 10.1016/j.prostaglandins.2006.06.004. View

11.

Weidner N, Semple J, Welch W, Folkman J . Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. N Engl J Med. 1991; 324(1):1-8. DOI: 10.1056/NEJM199101033240101. View

12.

Lou L, Jing D, Lai Y, Lu Y, Li J, Wu K . 15-PGDH is reduced and induces apoptosis and cell cycle arrest in gastric carcinoma. World J Gastroenterol. 2012; 18(10):1028-37. PMC: 3296976. DOI: 10.3748/wjg.v18.i10.1028. View

13.

Tatsuwaki H, Tanigawa T, Watanabe T, Machida H, Okazaki H, Yamagami H . Reduction of 15-hydroxyprostaglandin dehydrogenase expression is an independent predictor of poor survival associated with enhanced cell proliferation in gastric adenocarcinoma. Cancer Sci. 2009; 101(2):550-8. PMC: 11159708. DOI: 10.1111/j.1349-7006.2009.01390.x. View

14.

Gou H, Chen X, Zhu J, Jiang M, Yang Y, Cao D . Expressions of COX-2 and VEGF-C in gastric cancer: correlations with lymphangiogenesis and prognostic implications. J Exp Clin Cancer Res. 2011; 30:14. PMC: 3037339. DOI: 10.1186/1756-9966-30-14. View

15.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun M . Cancer statistics, 2009. CA Cancer J Clin. 2009; 59(4):225-49. DOI: 10.3322/caac.20006. View

16.

Tong M, Ding Y, Tai H . Reciprocal regulation of cyclooxygenase-2 and 15-hydroxyprostaglandin dehydrogenase expression in A549 human lung adenocarcinoma cells. Carcinogenesis. 2006; 27(11):2170-9. DOI: 10.1093/carcin/bgl053. View

17.

Wang D, DuBois R . Prostaglandins and cancer. Gut. 2005; 55(1):115-22. PMC: 1856377. DOI: 10.1136/gut.2004.047100. View

18.

Tennis M, VanScoyk M, Keith R, Winn R . The role of prostacyclin in lung cancer. Transl Res. 2010; 155(2):57-61. DOI: 10.1016/j.trsl.2009.06.010. View

19.

Liu Z, Wang X, Lu Y, Han S, Zhang F, Zhai H . Expression of 15-PGDH is downregulated by COX-2 in gastric cancer. Carcinogenesis. 2008; 29(6):1219-27. DOI: 10.1093/carcin/bgm297. View

20.

Wakimoto N, Wolf I, Yin D, OKelly J, Akagi T, Abramovitz L . Nonsteroidal anti-inflammatory drugs suppress glioma via 15-hydroxyprostaglandin dehydrogenase. Cancer Res. 2008; 68(17):6978-86. DOI: 10.1158/0008-5472.CAN-07-5675. View